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Abstract
We previously synthesized a series of potent and selective A3 adenosine receptor (AR) agonists
(North-methanocarba nucleoside 5′-uronamides) containing dialkyne groups on extended adenine
C2 substituents. We coupled the distal alkyne of a 2-octadiynyl nucleoside by Cu(I)-catalyzed “click”
chemistry to azide-derivatized G4 (fourth-generation) PAMAM dendrimers to form triazoles. A3AR
activation was preserved in these multivalent conjugates, which bound with apparent Ki 0.1–0.3 nM.
They were substituted with nucleoside moieties, solely or in combination with water-solubilizing
carboxylic acid groups derived from hexynoic acid. A comparison with various amide-linked
dendrimers showed that triazole-linked conjugates displayed selectivity and enhanced A3AR affinity.
We prepared a PAMAM dendrimer containing equiproportioned peripheral azido and amino groups
for conjugation of multiple ligands. A bifunctional conjugate activated both A3 and P2Y14 receptors
(via amide-linked uridine-5′-diphosphoglucuronic acid), with selectivity in comparison to other ARs
and P2Y receptors. This is the first example of targeting two different GPCRs with the same
dendrimer conjugate, which is intended for activation of heteromeric GPCR aggregates. Synergistic
effects of activating multiple GPCRs with a single dendrimer conjugate might be useful in disease
treatment.
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INTRODUCTION
Poly(amidoamine) (PAMAM) dendrimers are treelike polymers that have wide application in
drug delivery in vivo (1,2). We recently reported the first example of using a PAMAM
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dendrimeric scaffold for the polyvalent, nanoscale presentation of nucleosides and nucleotides
to selectively activate adenosine receptors (ARs) and P2Y receptors to induce intracellular
signal transduction (3–5). Both of these receptor families are cell-surface G protein–coupled
receptors (GPCRs). The dendrimer carriers greatly multiply the size of the monomer agonist
derivatives, and these multivalent conjugates are intended to bridge multiple binding sites
present in GPCR dimers and other higher-order receptor aggregates. In general, we might
expect the stability of the ligand in biological systems and its pharmacokinetic and
pharmacodynamic properties to be enhanced in the conjugates in comparison to the monomeric
ligands.
The A3AR is found at various levels of expression in neutrophils, eosinophils, cardiac
myocytes, skeletal muscle, astrocytes, neurons, and other cell types (6) and has distinct effects
on cell survival and response to stress. The A3AR agonist N6-(3-iodobenzyl)-5′-N-
methylcarboxamidoadenosine (IB-MECA, CF101) 1 (Chart 1) and its 2-chloro derivative
deregulate the NFκB pathway and are currently in clinical trials for the treatment of
autoimmune inflammatory diseases and cancer, respectively (7–11). Anti-ischemic effects of
A3AR agonists also suggest their use in protection of the heart, lung, nervous system, and
skeletal muscle (6,12,13).
We previously synthesized a series of North (N)-methanocarba nucleoside 5′-uronamides as
A3AR agonists of high affinity and selectivity (14). These selective agonists, including the
anti-ischemic nucleoside MRS3558 2, contained a rigid bicyclo[3.1.0]hexane (methanocarba)
ring system of the (N) conformation in place of the freely twisting ribose moiety (9,11,12).
These agonists also contained an optimized N6-(3-chlorobenzyl) group, which enhanced
A3AR selectivity in humans, mice, rats, and other species (14). Recently, we extended this
series to include dialkyne groups on an extended adenine C2 substituent, e.g., 3a (21). We
expected the proximal alkyne to promote receptor recognition and the distal alkyne to serve as
a site for coupling to reporter groups while maintaining receptor recognition. Thus, we have
selected a region on the nucleoside for attachment that is distal from the pharmacophore and
is predicted by modeling to extend into the extracellular region of the A3AR (15).
Here, we coupled the distal alkyne of an A3AR agonist containing a 2-octadiyne group to azido-
derivatized G4 (fourth-generation) PAMAM dendrimer carriers with Cu(I)-catalyzed alkyne-
azide cycloaddition, a type of click chemistry (16–18), to form triazole derivatives, as in
conjugate 3b, and determined the receptor-binding affinity and selectivity. This variation of
click chemistry was used previously for coupling biologically active molecules to polymers
(19). In our previous studies of dendrimer-bound ligands for GPCRs, the small molecular
ligands were amide-linked to the carrier (3–5). For this study, we compared the amide linkages
to PAMAM dendrimers with the use of azido groups for conjugation of alkyne derivatives.
We also included PAMAM dendrimers with mixed peripheral azido and amino groups in this
study. The incorporation of azides for click chemistry along with the conventional terminal
amino/carboxylic groups of the PAMAM dendrimers for amide coupling allowed the facile
conjugation of ligands for two different GPCRs (Figure 1). We present the first example of
coactivation of two GPCRs by a hybrid PAMAM dendrimer conjugate. The anti-inflammatory
A3AR and the P2Y14 receptor, which is activated by endogenous uridine-5′-diphosphoglucose
(UDPG) in the neuroimmune system (20), serve to illustrate this approach.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
Materials and Methods—All reactions were carried out under a nitrogen atmosphere. We
purchased N-ethyl-N′-dimethylaminopropylcarbodiimide hydrochloride (EDC.HCl), UDPG
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acid trisodium salt (UDPGA), UDPG, G2.5 PAMAM (10 wt% solution in methanol), G3
PAMAM (20 wt% solution in methanol), PAMAM dendrimers (G4, G5.5, and G6, 5 wt%
solution in methanol) with an ethylenediamine core from Sigma-Aldrich (St. Louis, MO). All
other reagents and solvents, except those indicated, came from Sigma-Aldrich. We purchased
dialysis membranes (Spectra/Pore Membrane, MWCO 3500, flat width 18 mm) from Spectrum
Laboratories (Rancho Dominguez, CA). Synthesis of compound 3a is described elsewhere
(21).
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker DRX-600 spectrometer
with D2O as a solvent. The chemical shifts are expressed as relative ppm from HOD (4.80).
We performed electrospray ionization mass spectrometry (MS) and matrix-assisted laser
desorption ionization (MALDI) time-of-flight MS experiments on a Waters LCT Premier mass
spectrometer at the Mass Spectrometry Facility, National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK), NIH. We analyzed the azido dendrimer precursors on a Varian
500 MHz NMR and on a Bruker Vertex 70 FT-IR. Galbraith Laboratories (Knoxville, TN)
performed the elemental analysis.
G4 PAMAM, Conjugated with 6-heptynoic acid (15)—We added freshly prepared
aqueous sodium ascorbate (1 M, 42 μL, 42.1 μmol) to a mixture of G4 PAMAM dendrimer
13 (6.74 mg, 0.42 μmol) and 6-heptynoic acid (1.33 mg, 10.5 μmol) in a mixture of t-butanol
(0.3 mL) and water (0.3 mL), then added 7.5% aqueous cupric sulfate (70 μL, 20.8 μmol). The
reaction mixture was stirred at room temperature overnight, and the product was purified by
dialysis in water. The mixture was lyophilized to yield compound 15 (5.45 mg, 68%) as a white
foamy solid. MALDI-MS: calcd. 19,029; found 18,928.
G4 PAMAM, Conjugated with A3AR Agonist 3a and 6-heptynoic Acid (7)—We
added freshly prepared aqueous sodium ascorbate (1 M, 31 μL, 31 μmol) to a mixture of
compound 15 (5.45 mg, 0.28 μmol) and compound 3a (4.13 mg, 7.74 μmol) in a mixture of t-
butanol (0.3 mL) and water (0.3 mL), then added 7.5% aqueous cupric sulfate (51 μL, 14.3
μmol). The reaction mixture was stirred at room temperature overnight, and the product was
purified by dialysis in water. The mixture was lyophilized to yield compound 7 (5.8 mg, 60%)
as a white foamy solid. 1H NMR (DMSO-d6, 600 MHz) δ 8.51 (s), 8.14 (s), 7.61 (s), 7.31–
7.41 (m), 5.46 (s), 5.68–5.95 (m), 3.86 (s), 2.66 (s), 2.21 (s), 1.8 (s), 1.61 (bs), 1.11–1.29 (m).
MALDI-MS: calcd. 33,852; found 34,088.
G4 PAMAM, Conjugated with A3AR Agonist 3a (6)—We followed the procedure used
for compound 7 to synthesize compound 6 (69%) from 3a. 1H NMR (DMSO-d6, 400 MHz)
δ 8.50 (bs), 8.15 (bs), 7.60 (s), 7.29–7.59 (m), 5.44 (s), 4.67–5.05 (m), 4.16 (s), 3.86 (s), 2.78
(s), 2.67 (s), 2.08–2.23 (m), 1.82 (s), 1.61 (s), 0.98–1.30 (m). MALDI-MS: calcd. 49,991; found
50,844.
G4 PAMAM, Conjugated with UDPGA (17)—We added EDC.HCl (12.5 mg, 65.2 μmol)
to a solution of compound 5 (15.3 mg, 1.01 μmol) and UDPGA trisodium salt 16 (22.9 mg,
35.43 μmol) in dimethylsulfoxide (DMSO), then added 0.1 M 2-(N-morpholino)ethanesulfonic
acid buffer (140 μL). We used 0.1 M HCl to adjust the pH of the reaction mixture to 4.5–5.0.
The reaction mixture was stirred at room temperature overnight, and the product was purified
by extensive dialysis followed by lyophilization to yield compound 17 (22 mg, 64%). 1H NMR
(DMSO-d6, 400 MHz) δ 8.19 (s), 7.86–8.14 (m), 6.55 (m), 5.80 (s), 5.67 (s), 5.38–5.47 (m),
4.07 (s), 3.97 (s), 3.63 (br s), 3.25 (s), 3.12 (s), 2.91 (s), 2.69 (s), 2.24 (s). MALDI-MS: calcd.
33,060; found 33,036.
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G4 PAMAM, Conjugated with UDPGA and A3AR Agonist 3a (8)—We followed the
procedure used for compound 7 to synthesize compound 8 (66%) from compound 17. MALDI-
MS: calcd. 50,092; found 50,610.
G2.5 PAMAM, Conjugated with A3AR Agonist 19 (9)—We followed the procedure
used for compound 17 to synthesize compound 9 (54%) from dendrimer 18 and compound
19. 1H NMR (D2O, 600 MHz) δ 7.98 (br s), 6.88 (br s), 4.56 (br s), 3.85 (br s), 3.55 (br s), 3.45
(br s), 3.16–3.36 (m), 3.16 (br s), 3.08 (br s), 2.56–2.98 (m), 2.54 (s), 2.24–2.48 (m), 1.92 (br
s), 1.68 (br s). MALDI-MS: calcd. 10,598; found 10,783.
G2.5 PAMAM, Conjugated with A3AR Agonist 20 (10)—We followed the procedure
used for compound 17 to synthesize compound 10 (67%) from dendrimer 18 and compound
20. 1H NMR (DMSO-d6, 600 MHz) δ 8.11 (s), 7.85–8.01 (m), 7.58 (s), 7.36 (s), 7.18–7.32
(m), 5.06–5.21 (m), 4.88–4.93 (m), 4.65 (s), 4.59 (s), 3.86–3.91 (m), 3.07 (s), 2.65 (s), 2.39
(s), 2.21 (s), 1.85 (s), 1.74 (br s), 1.59 (br s), 1.21–1.33 (m), 1.03 (br s). MALDI-MS: calcd.
8370; found 8369.
G3 PAMAM, Conjugated with A3AR Agonist 22 (11)—We followed the procedure used
for compound 17 to synthesize compound 11 (71%) from dendrimer 21 and compound
22. 1H NMR (DMSO-d6, 600 MHz) δ 8.88 (s), 8.11 (s), 7.73–8.05 (m), 7.58 (s), 7.32 (s), 7.13–
7.28 (m), 5.43 (s), 5.03–5.21 (br s), 4.87–4.96 (s), 4.85 (br s), 4.67 (s), 4.61 (s), 3.89 (s), 3.06
(s), 2.82 (s), 2.65 (s), 2.34–2.46 (m), 2.19 (s), 1.83 (s), 1.69–1.78 (m), 1.61 (s), 1.29 (s). MALDI-
MS: calcd. 13,694; found 13,304.
G4 PAMAM, Conjugated with A3AR Agonist 24 (12)—We added HATU (4.67 mg,
12.28 μmol) to a mixture of compound 24 (6.72 mg, 12.35 μmol) and dendrimer 23 (2.73 mg,
12.28 μmol) in dry DMF (0.5 mL), then added DIPEA (2.15 μL, 12.22 μmol). The reaction
mixture was stirred at room temperature overnight, extensively dialyzed with water, then
lyophilized to yield compound 12 (5.5 mg, 61%). 1H NMR (DMSO-d6, 400 MHz) δ 8.46 (br
s), 8.10 (s), 7.79–7.93 (m), 7.60 (s), 7.27–7.36 (m), 5.45 (s), 4.67–4.93 (m), 3.87 (s), 3.08 (s),
2.86 (s), 2.66 (s), 2.41 (s), 2.19 (s), 1.78 (s), 1.61 (s), 1.23 (t, J = 24 Hz), 0.80–0.89 (m). MALDI-
MS: calcd. 47,495; found 47,985.
Imidazole-1-sulfonyl azide hydrochloride (26)—A modification of a published
procedure was used (22). A suspension of 6.53 g NaN3 (25, 100 mmol, Aldrich, >99.5%) and
100 mL acetonitrile (Aldrich, 99.8% anhydrous) in a 500-mL round-bottom flask was cooled
in an ice water bath under a flow of nitrogen. We then added 8.15 mL sulfuryl chloride (100
mmol, TCI American, >98.0%) in 20 mL) anhydrous acetonitrile drop-wise to the ice-cooled
suspension. The mixture was stirred overnight at room temperature, after which we cooled the
white suspension to ~0°C with ice water and added 13.03 g imidazole (191 mmol, TCI America,
>98.0%). We warmed the resulting white slurry to room temperature, then stirred it for 3 h.
We then diluted it with ethyl acetate (200 mL) and separated and discarded the aqueous layer.
We washed the organic layer twice with deionized water (2 × 100 mL), then twice with saturated
aqueous NaHCO3 (2 × 100 mL). We then dried it over anhydrous MgSO4 overnight and filtered
it. We added an ethanolic HCl solution (196 mmol) drop-wise to the filtrate while stirring at
ice-water temperature. After we added ~3 mL, a large amount of white solid appeared. We
kept the mixture in an ice bath for 15 min, then at room temperature for 30 min, after which
we filtered it. We washed the filter cake with ethyl acetate (3 × 100 mL) to give 26 as a colorless
solid (8.65 g, 49.9%), m.p. 99–101°C. IR (KBr) 2173, 1383 and 1160 cm−1. 1H NMR (500
MHz, D2O) d 7.61 (dd), 8.02 (dd), 9.39 (dd); 13C NMR (125. MHz, D2O) δ = 120.0, 123.5,
137.6. Element Analysis: Calculated C, 17.19; H, 1.92; N, 33.41. Found: C, 17.38; H, 1.98; N,
32.97.
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Synthesis of Fully Azido-Derivatized PAMAM (G4) (13)—We added anhydrous
methanol (10 mL, Aldrich, >99.8%) and 18.15 g G4 PAMAM dendrimer (23, Dendritech,
Midland, MI, 14.93 w/w% in methanol, [NH2]=12.2 mmol) to a 250-mL round-bottom flask.
We then added 3.12 g K2CO3 (Aldrich, >99.0%, 22.6 mmol) and 31.4 mg CuSO4.5H2O
(Aldrich, 98.0%, 0.126 mmol), causing the solution to take on a pale bluish color. We next
added 2.73 g imidazole-1-sulfonyl azide hydrochloride (26, 13.1 mmol) to the reaction mixture,
and it was stirred at room temperature overnight. The mixture was then dialyzed against
deionized water for 7 d, during which we changed the water every 2 h for the first 2 d and
thereafter every 4 h. After lyophilization, we collected 2.51 g azide-derivatized G4 dendrimer.
The proton NMR is shown in Figure 2. Element analysis: PAMAM-G4: calculated: C, 52.81;
H, 8.48; N, 24.70, O, 14.01; fully azide-derivatized G4 PAMAM calculated: C, 47.03; H, 7.15;
N, 33.31, O, 12.49; Found: C: 49.91; H: 7.55; N: 28.07, O: 13.12. The element analyses
indicated that 98.0%of primary amines were replaced with azides.
Synthesis of Partially Azido-Derivatized PAMAM (G4) (5)—We added anhydrous
methanol (5 mL, Aldrich, >99.8%) and 5.13 g G4 PAMAM dendrimer (23, Dendritech, 14.93
w/w% in methanol, [NH2]=3.45 mmol) to a 100-mL round-bottom flask. We then added 0.803
g K2CO3 (Aldrich, >99.0%, 5.81 mmol) and 17.2 mg CuSO4.5H2O (Aldrich, 98.0%, 0.069
mmol); the solution took on a pale-bluish color. Next we added 0.43 g imidazole-1-sulfonyl
azide hydrochloride (26, 2.05 mmol) to the reaction mixture, which was stirred at room
temperature overnight. We then dialyzed the mixture against deionized water for 7 d, changing
the water every 2 h during the first 2 d and every 4 h thereafter. After lyophilization, we
collected 0.45 g partially azide-derivatized G4 dendrimer. Elemental analysis of the partially
azide-derivatized G4 PAMAM found C: 49.91 H: 7.55; N: 28.07; O: 13.12. We compared
results of the element analysis with the composition of the G4 PAMAM dendrimer and found
that 47.2% of the primary amines were replaced with azides, corresponding to ~31 amines per
dendrimer in 64 terminal positions.
Biological Methods: P2Y14 Receptor
Materials—We purchased 3-isobutyl-1-methyl-xanthine from Sigma-Aldrich and [3H]
adenine from American Radiolabeled Chemicals (St. Louis, MO). We obtained all cell culture
medium and serum from Gibco(Invitrogen, Carlsbad, CA).
Cell culture—We generated C6 glioma cells stably expressing the human P2Y 14-R
(P2Y14-C6 cells) as previously described by Fricks et al. (23). We cultured P2Y14-C6 cells in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum,
1% Geneticin (Gibco), and 1% antibiotic-antimocotic (Gibco) at 37°C in a 5% CO2
environment.
Accumulation of adenosine 3′, 5′-cyclic phosphate (cAMP)—We grew P2Y14-C6
cells in 24-well plates and incubated them with 1 μCi [3H]adenine/well in serum-free DMEM
for at least 2 h prior to assay. We initiated the assays by adding HEPES-buffered, serum-free
DMEM containing 200 μM 3-isobutyl-1-methyl-xanthine and 30 μM forskolin, with or without
drugs, and incubation continued for 15 min at 37°C. We terminated incubations by aspirating
the medium and adding 450 μL ice-cold 5% trichloroacetic acid. We isolated [3H]cAMP by
sequential Dowex and alumina chromatography and quantified it by liquid scintillation
counting as previously described by Harden et al. (24).
Data analysis—We measured the concentrations of the dendrimer-ligand complexes by the
concentration of the dendrimer, not the attached ligand. We determined EC50 and apparent
Ki values with Prism software (GraphPad, San Diego, CA); they are presented as mean ± SE.
The number of nucleoside moieties on a given dendrimer that are accessible to receptors is
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uncertain; the data are therefore shown as apparent Ki values. We repeated all experiments at
least three times.
Biological Methods: ARs
Receptor-binding and functional assays—We obtained [3H]adenosine-5′-N-
methyluronamide ([3H]NECA, 42.6 Ci/mmol) from PerkinElmer Life and Analytical Science
(Boston, MA). We purchased [3H](2-[p-(2-carboxyethyl)phenyl-ethylamino]-5′-N-
ethylcarboxamido-adenosine) ([3H]CGS21680, 40.5 Ci/mmol) and [125I]N6-(4-amino-3-
iodobenzyl)adenosine-5′-N-methyluronamide ([125I]I-AB-MECA, 2200 Ci/mmol) from
PerkinElmer. We prepared test compounds as 5-mM stock solutions in DMSO and stored them
frozen at −20°C.
Cell culture and membrane preparation—We cultured Chinese hamster ovary (CHO)
cells stably expressing the recombinant hA1 and hA3 and human embryonic kidney (HEK) 293
cells stably expressing the hA2AAR in DMEM and F12 (1:1) supplemented with 10% fetal
bovine serum, 100 units/mL penicillin, 100 μg/mL streptomycin, and 2 μmol/mL glutamine.
In addition, we added 800 μg/mL Geneticin to the A2A media and 500 μg/mL hygromycin to
the A1 and A3 media. After harvesting the cells, we homogenized them with an electric
homogenizer for 10 sec, pipetted them into 1-mL vials, and then stored them at −80°C until
we conducted the binding experiments. We measured the protein concentration with a BCA
Protein Assay Kit from Pierce Biotechnology (Rockford, IL) (25).
Binding assays—Each tube in the binding assay contained 50 μL of increasing
concentrations of the test ligand in Tris-HCl buffer (50 mM, pH 7.5) containing 10 mM
MgCl2, 50 μL of the appropriate agonist radioligand, and 100 μL membrane suspension, added
sequentially. For the A1AR (20 μg protein/tube), we used the radioligand [3H]NECA (~3.5
nM, precise final concentration is calculated for each experiment). For the A2AAR (20 μg/
tube), we used the radioligand[ 3H]CGS21680 (~10 nM). For the A3AR (21 μg/tube), we used
the radioligand [125I]I-AB-MECA (~0.3 nM). We determined nonspecific binding with a final
concentration of 10 μM unlabeled NECAdiluted with the buffer. We incubated the mixtures
at 25°C for 60 min in a shaking water bath. We terminated binding reactions by filtration
through Brandel GF/B filters under a reduced pressure with a M-24 cell harvester (Brandel,
Gaithersburg, MD). We washed filters three times with 3 mL 50-mM ice-cold Tris-HCl buffer
(pH 7.5). We then placed filters for A1 and A2AAR binding in scintillation vials containing 5
mL Hydrofluor scintillation buffer and counted with a PerkinElmer Liquid Scintillation
Analyzer (Tri-Carb 2810TR). We counted filters for A3AR binding with a Packard Cobra II
γ-counter (PerkinElmer). We determined the Ki values with GraphPad Prism for all assays.
Accumulation of cAMP—To determinecAMP production (26), we incubated protein kinase
A with [3H]cAMP (2 nM) in K2HPO4/EDTA buffer (K2HPO4, 150 mM; EDTA, 10 mM), 20
μL cell lysate, and 30 μL 0.1 M HCl or 50 μL cAMP solution (0–16 pmol/200 μL for standard
curve). We separated bound radioactivity by rapid filtration through Whatman GF/C filters




We prepared various PAMAM dendrimer derivatives of nucleosides and nucleotides (Table
1, 6–12) to act as multivalent ligands of GPCRs. The peripheral groups of the precursor
dendrimers contained either all azido groups (Scheme 1), mixtures of azido and amino groups
(Scheme 2), or the conventional all amino/carboxylate groups (Scheme 3). The synthetic
Tosh et al. Page 6













methods used to partially or fully substitute terminal amino groups of a G4 PAMAM dendrimer
with azides are shown in Scheme 4 (22).
We recently introduced terminal alkynyl groups at the C2 position of (N)-methanocarba
nucleoside derivatives to serve as sites on the A3AR agonists for cross-linking by click
chemistry (21). Thus, a dialkyne was introduced at the C2 position in 2, and further reaction
with azides generally occurred exclusively at the distal alkyne. Prior to coupling the nucleosides
to dendrimer carriers, we explored in detail the structure-activity relationship at the distal region
of an alkyne-functionalized chain at the 2 position and the resultant click products (21).
The synthetic route to the multivalent dendrimer conjugates of nucleosides for activation of
the A3AR that contain 5′-N-methyluronamide (N)-methanocarba 2-alkynyl triazoles 6 and 7
is shown in Scheme 1. Click chemistry efficiently coupled the A3AR agonist 3a to a PAMAM
dendrimer fully substituted with peripheral azido groups. We used two versions of this azido-
functionalized dendrimeric scaffold: 15, containing extra appended carboxylic acid groups for
increasing water solubility, and 13, lacking these groups. We added the carboxylic acid
moieties to the azido dendrimer 13 by partial reaction of the peripheral azido groups with
hexynoic acid 14. Thus, we prepared two nucleoside-containing dendrimer derivatives 6 and
7. Derivative 6 was fully substituted with the adenosine analogue, with 64 nucleoside moieties
per dendrimer molecule. Derivative 7 was partially (28 out of 64) substituted with the adenosine
analogue and contained 24 carboxylic acid moieties. 12 azido groups per molecule of 7
remained unreacted.
In the next phase of our study, we combined different GPCR ligands, i.e., the A3AR and another
receptor, on the same dendrimer carrier. We selected the P2Y14 receptor, which is activated
by naturally occuring uridine-5′-diphosphoglucose (UDPG), for this purpose because, like the
A3AR, it occurs on immune cells and because we recently introduced high-potency dendrimer
conjugates for this subtype (5,27). Each ligand would provide selectivity for a particular GPCR
subtype, and the overall selectivity of the conjugate would be a function of the union of the
sets of selectivity of the attached nucleosides. We sequentially coupled alkyne and carboxylic
acid derivatized ligands for the two receptors to a novel multifunctional PAMAM dendrimer.
Thus, alkynes reacted exclusively with azido terminal groups and carboxylic acids with
terminal amino groups on the same dendrimer to randomly (but in a defined ratio) produce a
multivalent, binary conjugate.
We proceeded to synthesize a multivalent, binary conjugate of a mixed azido/amino dendrimer
5, as shown in Scheme 2. In the dendrimer precursor 5, we determined, through NMR (28)
(Figure 2) and elemental analysis, that the ratio of amines to azides was ~31:33. Therefore, of
the 64 terminal groups on each G4 dendrimer, ~33 would be available for cycloaddition, and
the remaining terminal groups would be available for amide formation. We first coupled the
amino groups of 5 to the functionalized, P2Y14-selective nucleotide UDPGA 16, which we
previously showed to be a suitable functionalized congener for chain attachment without loss
of receptor activation (5). We then coupled the azido groups of 17 to the functionalized
nucleoside 3a, which is a suitable functionalized congener for chain attachment without loss
of binding affinity at the A3AR (21). The product of this second coupling reaction was the
mixed dendrimer 8, in which the average ratio of content of UDGPA and nucleoside moieties
was ~31:33 per G4 dendrimer. Thus, conjugate 8 would be expected to potently activate both
A3 and P2Y14 receptors and perhaps maintain selectivity over other ARs and P2Y receptors.
To compare alkyne-azide click chemistry with the more standard amide formation as a means
of linking A3AR-selective agonists to PAMAM dendrimers, we prepared various dendrimer
derivatives starting with our previously reported amino and carboxylic-functionalized
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congeners 19, 20, 22, and 24 (14,15). The reaction sequences are shown in Scheme 3. We
included a variety of dendrimer sizes and sites of conjugation on the nucleoside.
The synthesis of the PAMAM dendrimer intermediate 5 containing equiproportioned
peripheral azido and amino groups for conjugation of multiple ligands is shown in Scheme 4.
We used the reagent imidazole-1-sulfonyl azide hydrochloride 26 for the conversion of
peripheral amino groups to azido groups (22). We prepared a fully azido-derivatized G4
dendrimer 13 similarly and used it to synthesize conjugates 6 and 7.
Quantification of Pharmacological Activity
We tested the dendrimer nucleoside conjugates similarly in binding assays at three hAR
subtypes; we used standard radioligands (29–31) and membrane preparations from CHO cells
(A1 and A3) or HEK293 cells (A2A) stably expressing a hAR subtype (Table 1) (32,33). We
used the previously reported agonist molecular probes of the A3AR (1,2, 3a, and 4) for
comparison in the biological assays (15,21).
We included the parent dendrimer 5, which contained both amino and azido groups, as a
control; it was inactive in AR binding at 1 μM. We considered compound 4a to be a model
compound for the attachment of the 2-octadiyne derivative 3a to azido-bearing PAMAM
dendrimers by click chemistry. As reported previously, the triazole-containing monomer 4a
maintained both high potency and selectivity (at least 100-fold) for the A3AR (21).
The multivalent dendrimer derivatives 6 and 7 obtained from 3a through click conjugation
were considerably more potent than 4a in binding assays at the A1, A2A, and A3 ARs. The
affinity of 6 and 7 in binding to the A3AR was particularly high, with Ki values of 0.1–0.3 nM
(Figure 3). The fully substituted dendrimer 6 was only 2.3-fold more potent at the A3AR than
the less heavily loaded 7, which was substituted with nucleosides at 44% of the theoretically
available terminal positions. The selectivity of these dendrimer conjugates for the A3AR in
comparison to the A1AR was still present (161- and 110-fold for 6 and 7, respectively) but
diminished in comparison to the monomer 4a (>500-fold). However, the A3AR selectivity of
6 (230-fold) and 7 (180-fold) in comparison to the A2AAR was similar to that of 4a. Thus, the
presence of the carboxylic acid chain in 7 had only minor effects on the observed AR affinity
and selectivity, but it increased the observed aqueous solubility. Both 6 and 7 were readily
soluble in DMSO at a concentration of 1 mM, but when we diluted the DMSO stock solutions
with phosphate-buffered saline for a final calculated concentration of 30 μM, we observed
some cloudiness in 6 but not in 7.
Dendrimer derivative 8 contained an additional covalently bound GPCR ligand, a nucleotide
designed to activate the P2Y14 receptor. We found that combining strategically functionalized
nucleosides and nucleotideson the same dendrimer carrier —for example, to activate both
adenosine and P2Y receptors—provided high-affinity recognition at both GPCRs. However,
the Ki value of 8 in binding to the A3AR (39.5 nM) indicated that it was considerably less
potent than the conjugates 6 and 7, which contained only the A3AR agonist ligand. The A3AR
selectivity of 8 was only 2-fold in comparison to the A1AR and 15-fold in comparison to the
A2AAR. Thus it was much less A3AR selective than were 6 and 7.
A functional assay of adenylate cyclase inhibition carried out in C6 cells expressing the human
P2Y14 receptor demonstrated that potency at this receptor was enhanced in the dendrimer
conjugate 8 over that of the monomer, with an EC50 value of 2.24 ± 0.80 nM (Figure 4). Both
UDPG and UDPGA displayed potencies in the same assay of 200–300 nM (5). This degree of
potency enhancement at the P2Y14 receptor was consistent with previous results of conjugation
of UDPGA derivatives to PAMAM carriers (5). Dendrimer 17, which contained only the ligand
of the P2Y14 receptor (i.e., 31 nucleotides bound per G4 dendrimer) and not the A3AR-
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activating moiety, displayed an EC50 value at the P2Y14 receptor of 2.41 ± 0.77 nM. Curiously,
nucleotide-containing dendrimers 8 and 17 also interacted with at least one other subtype of
P2Y receptor, but nevertheless with selectivity for the P2Y14 receptor. Dendrimers 8 and 17
displayed EC50 values in activation of phospholipase C (PLC) by the human P2Y2 receptor of
1.39 ± 0.54 μM and 733 ± 223 nM (n = 3), respectively, assayed as described in stably
transfected 1321N1 astrocytoma cells (34). The native agonist of the P2Y14 receptor, UDPG,
also activated the human P2Y2 receptor, with an EC50 value of 10 μM (34).
PAMAM dendrimer conjugates (9–12) of carboxylic- and amino-functionalized congeners of
A3AR-selective agonists consistently displayed lower affinity in A3AR binding than did the
click-linked dendrimers 6 and 7. The amide-linked conjugates included derivatives of both
terminal carboxylic acid–functionalized dendrimers 9 and 10 and terminal amine-
functionalized dendrimers 11 and 12, ranging from generation 2.5 to 4. The affinities of these
dendrimers at the hA3AR were in the range of 12–42 nM, and the nature of the residual terminal
groups of the dendrimer carrier had little effect. We did not observe the subnanomolar affinity
seen in click-linked nucleoside-dendrimer conjugates. Thus, the high affinity is partially the
result of the linkers and the coupling chemistry used, which in 6 and 7 produce a triazole rather
than an amide linkage.
The selectivity of the amide-linked dendrimers in comparison to the A2AAR was high (×-fold,
for compound): >300, 9; ≫24, 10; 327, 11; 62, 12. However, there was a substantial gain in
affinity at the A1AR over the corresponding monomeric nucleosides. Thus, 10 and 11 lost
selectivity for the A3AR in comparison to the A1AR. Compound 12 was reversed in its
selectivity (6-fold more potent at the A1AR than at the A3AR). Conversely, we considered
compound 4b to be a model nucleoside derivative for the amide-linked dendrimer derivatives
9 and 12, and it was clearly A3AR selective. Compound 4c (63-fold selective for the A3AR
versus the A1AR) was a model for N6-functionalized dendrimer conjugates 10 and 11, although
it was a higher homologue with 4 methylenes. Thus, both model compounds 4b and 4c were
more potent and selective in binding to the A3AR than were the corresponding amide-linked
dendrimers.
We determined binding at the rat A3AR expressed in CHO cells for selected compounds. The
Ki values of the N6-chain derivatized, amide-linked dendrimers 10 and 11 were 62.0 ± 36.5
and 4.94 ± 1.96 nM (n = 3), respectively. The triazole-linked adenosine conjugate 7 with water-
solubilizing groups displayed a Ki value of 0.08 ± 0.02 nM in binding to the rat A3AR. Thus,
there was a relatively low degree of species-dependent variation in the observed A3AR affinity
(4-fold greater in rat than human).
We tested the nucleoside conjugates in a functional assay at the A3AR (inhibition of forskolin-
stimulated cAMP production in A3AR-expressing CHO cells) as shown in Table 2. These
multivalent derivatives displayed A3AR agonist properties with varying degrees of maximal
inhibition of forskolin-stimulated cAMP production at 0.1–10 μM (concentration selected to
be in >100-fold excess of the Ki value for each). In general, the relative efficacy was similar
to that of NECA (1 μM), taken as a reference standard. The dendrimer control was inactive.
The EC50 value of the amide-linked adenosine conjugate 11 was 2.93 ± 0.37 nM, determined
with a full curve in CHO cells stably expressing the human A3AR (Figure 5). Conjugate 11
was a full agonist in the A3AR-mediated inhibition of cAMP production. We also determined
EC50 values for cAMP inhibition with full curves for the triazole-linked adenosine conjugate
with water-solubilizing groups 7 (0.12 nM) and 8 (1.36 nM).
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We used the Cu(I)-catalyzed alkyne-azide click reaction for linking functionalized congeners
of AR ligands (21,35) to other moieties, specifically PAMAM dendrimer derivatives. In this
study, we compared different chemical strategies for tethering GPCR ligands to
macromolecular carriers. Dendrimer derivatives prepared by click chemistry were particularly
potent and selective in binding to the A3AR. Multivalent nucleoside-dendrimer conjugates 6
and 7 showed much greater A3AR affinity than the corresponding monomer, the model
nucleoside 4a. Furthermore, amide-linked nucleoside conjugates were considerably weaker
than click-linked conjugates in binding to the A3AR. This illustrates the dramatic effect that
both the multivalency and the intermediate structures contained within the functionalized chain
can have on interaction with the target receptor (35). A comparison with various amide-linked
dendrimers showed that the triazole linkage had a general A3AR affinity–enhancing effect.
Click chemistry was previously used to link small molecules to dendrimeric structures, but
ours was the first application for studying PAMAM dendrimer derivatives of small-molecular
GPCR ligands. Recently, peptide ligands were conjugated to dendrimers by click chemistry
for activation of a GPCR (18).
Other studies have focused on PAMAM dendrimers as reversible drug carriers, for example,
to deliver anticancer drugs that dissociated at the site of action (36). Our approach derivatizes
a small molecule but allows it to remain active while covalently attached to the carrier (35).
The binding sites of the receptors are accessible from the extracellular medium. Thus,
activation of the desired receptor would not benefit from either drug release or cellular
internalization of the dendrimer. The flexible dendrimer conjugate is available to spread over
the cell surface and to adopt a conformation that can bridge multiple binding sites (37).
The efficiency of the click reaction readily allowed complete substitution in the case of one of
the dendrimer derivatives, i.e., 6. In previous experiences with amide coupling of
functionalized nucleosides, we encountered difficulty in the complete substitution of amine-
terminated dendrimers (3,4). Click chemistry proved to be a more efficient coupling technique
and allowed orthogonal reaction control over the coupling chemistry when two distinct receptor
ligands were bound to the same dendrimer carrier (as in 8).
This study presents the first example of targeting two different GPCRs with the same dendrimer
conjugate, intended for activation of heteromeric aggregates of GPCRs. Each ligand provided
selectivity for a particular GPCR subtype, and the overall selectivity of the conjugate was a
function of the union of the sets of selectivity of the attached nucleosides. Specifically, the
dendrimer conjugate 8 contained ligands for both the A3AR and the P2Y14 receptor. The
principle of attachment of UDPG derivatives to PAMAM dendrimers to enhance potency was
introduced previously (5). This bifunctional dendrimer potently activated both A3 and P2Y14
receptors, although not to the exclusion of other ARs.
The bifunctional dendrimer 8 and its nucleotide-dendrimer precursor 17 both activated one
other P2Y receptor examined, the hP2Y2 receptor, with intermediate potency. UDPG itself
activates the hP2Y2 receptor with an EC50 of 10 μM for stimulation of PLC in stably transfected
1321N1 cells (34). Therefore, the potency at both subtypes of P2Y receptors was much greater
in the dendrimer conjugates than in the monomer, but the desired selectivity for the P2Y14
receptor was maintained. Thus, both covalently tethered GPCR ligands, which were previously
shown to be suitable functionalized congeners for coupling to carriers, retained their activity
as the mixed dendrimer conjugate 8. This conjugate had reduced A3AR affinity in the presence
of tethered nucleotide moieties, but not reduced P2Y14 potency due to the tethered nucleoside
moieties. This is the first example of targeting two different GPCRs with the same dendrimer
conjugate, which is intended for activation of heteromeric aggregates of GPCRs.
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Many examples exist of two small molecules linked with a spacer group to make binary
conjugates for activation of two different GPCRs (35,38,39). Some researchers have
systematically varied the length of the spacer to achieve the correct fit to the two adjacent
binding sites. This multivalent approach was taken in part because of uncertainty about the
geometric orientation of protomer binding sites in a GPCR dimer. Flexible dendritic carriers
facilitate empirical testing of a variety of spatial orientations of the same conjugate. This
obviates the need to probe the optimal geometry a priori of a single spacer chain to achieve
simultaneous binding to two sites.
Both A3 and P2Y14 receptors are distributed in the immune system and appear to occur on the
same cell, as was shown for RBL-2H3 mast cells (27). Further experiments will be needed to
determine whether heteromers composed of A3 and P2Y14 receptors exist and whether this
conjugate is capable of bridging the binding sites on both protomers. This approach of mixing
receptor ligands on the same dendrimer carrier can be extended to many other combinations
of GPCRs.
We know that GPCRs tend not to be evenly or randomly distributed over the surface of a given
cell; we demonstrated this for the A3AR expressed heterologously in CHO cells (4). In general,
GPCRs may exist as complexes with other receptors and associated proteins. The receptors to
which a given GPCR pairs or forms a higher-order aggregate can dramatically affect its
pharmacology, and the binding of agonist to both protomers does not have equivalent
pharmacological effects (40). We lack effective ligand tools for separating the effects of one
receptor dimeric combination from another. This approach of mixing ligands for two different
receptors (35,38,39,41) promises to be a means of achieving selectivity for receptors in a given
tissue, based on association or aggregation of GPCRs, in comparison to another tissue in which
the same receptor may be alternatively paired. At this early stage, we do not know the
topological requirements for selectively targeting these combinations of receptors, because we
are just beginning to detect their existence. The multivalent binding to other types of cell surface
receptors has been explored through structural modification of the carrier polymer (42).
Multivalent conjugates of GPCR ligands provide quantitatively and qualitatively different
pharmacological properties than do monomers. Prosthetic groups for targeting or therapeutic
purposes or reporter groups for diagnostic purposes might be introduced. Specific
combinations of receptor ligands on the same dendrimer carrier might achieve synergistic
effects and prove useful for disease treatment, such as inflammatory conditions, to which the
current example of adenosine and P2Y receptor ligands apply. Various combinations may be
proposed for targeted therapeutic applications, but the linking strategy to achieve the desired
potency and selectivity still requires development. We are working on prototypical examples
that could be applied to other combinations of dendrimer-bound GPCR ligands.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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GPCR G protein–coupled receptor
IBMX 3-isobutyl-1-methylxanthine
AR adenosine receptor
cAMP adenosine 3′,5′-cyclic phosphate
CHO Chinese hamster ovary
IB-MECA N6-(3-iodobenzyl)-5′-N-methylcarboxamidoadenosine
DMEM Dulbecco’s modified Eagle’s medium
EDTA ethylenediaminetetraacetic acid
GPCR G protein–coupled receptor
HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium
hexafluorophosphate methanaminium
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Design of a bifunctional PAMAM dendrimer conjugate for the coactivation of two different
GPCRs; shown here are agonists of the A3AR and the P2Y14 receptor. Both receptors are
distributed in the immune system and may occur on the same cell (27). The stoichiometry of
substitution of the dendrimer is not indicated.
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1H NMR spectra of G4-N3 (5, top), G4-NH2 from D2O (23, middle). Schematic indication of
assignments of the methylene groups (bottom).
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Inhibition of radioligand binding by dendrimer nucleoside conjugates in membranes of CHO
cells expressing the human A1 (A) and A3 (C) ARs and HEK-293 cells expressing the human
A2AAR (B). Inhibition curves at three ARs are shown for the dendrimer-nucleoside conjugates
6 and 7, in which the linkage to an azide-derivatized dendrimer was formed by click
cycloaddition, for the mixed nucleoside/nucleotide conjugate 8 and for the amide-linked
nucleoside conjugate 12. Both 6 and 7 were highly selective for the hA3AR in comparison to
the hA1 and hA2AARs.
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Activation of the Gi-coupled P2Y14 receptor stably expressed in C6 cells by the mixed
nucleoside/nucleotide G4 dendrimer conjugate 8 (MRS5259) and the nucleotide G4 dendrimer
conjugate 17 (MRS2949). Inhibition of forskolin (FSK)-stimulated cAMP is shown in
comparison to the effects of UDPG (n = 3).
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Activation of the Gi-coupled A3AR stably expressed in CHO cells by 11. The agonist effect
measured is inhibition of forskolin-stimulated cAMP production, in comparison to the maximal
effect of a full agonist NECA at 1 μM. Curve is representative of three determinations.
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Use of click chemisry to synthesize PAMAM dendrimer derivatives 6 and 7, containing a
functionalized 2-alkynyl A3AR agonist. An optional water-solubilizing group was added in
7, in the form of an aliphatic carboxylic acid.
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Synthesis of two PAMAM dendrimer derivatives containing a functionalized agonist of the
P2Y14 receptor derived by amide linkage of UDPGA 16. Conjugate 17 contains only the
P2Y14 receptor agonist; conjugate 8 contains an A3AR agonist linked through a click reaction
of its 2-alkynyl functionalized chain. The dendrimer precursor 5 contained a random
distribution of peripheral amino and azido groups in a ratio of ~33:31.
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Preparation of amide-linked nucleoside conjugates of PAMAM dendrimers.
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Synthesis of azido-derivatized PAMAM dendrimers, which served as precursors for the GPCR
ligand conjugates by reacting with imidazole-1-sulfonyl azide hydrochloride 26.
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Structures of adenosine A3AR agonist monomers (1–3) and the design of multivalent
dendrimer conjugates in the(N) -methanocarba series, represented by the triazole derivative of
general formula (4). Compound 3a was reported in ref. 9.
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Table 1
Potency of a series of nucleoside-dendrimer conjugates at three subtypes of human ARs.
Compd Structure, R1, R2, or R3






2b,c R1 = Cl 260±60h 2300±100 0.29±0.04





4ab,c R2 = (CH2)2NHCOCH3 (12±4%)
at 10 μM
2440±320 22.3±1.6
4bb R1 = C≡C(CH2)2CH3 1040±80 (80%) at 10
μM
0.82±0.20




5d NA NA NA
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Compd Structure, R1, R2, or R3
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Compd Structure, R1, R2, or R3
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Compd Structure, R1, R2, or R3






All experiments were done on CHO or HEK293 (A2A only) cells stably expressing one of four subtypes of human ARs. The binding affinity for
A1, A2A, and A3ARs was expressed as Ki values (n = 3–5) and was determined by using agonist radioligands ([3H]NECA, [3H]CGS21680, or
[125I]I-AB-MECA, respectively), unless noted. A percentage in parentheses refers to inhibition of radioligand binding at the indicated concentration.
The concentrations of the dendrimer-ligand complexes were measured by the concentration of the dendrimer, not the ligand. Therefore, all binding
Ki values of dendrimers are expressed as Kiapp values.
b
Affinity values from Tosh et al. (15,21) and Melman et al. (14).
c
2, MRS3558; 3a, MRS5221; 4a, MRS5233; 6, MRS5246; 7, MRS5247; 8, MRS5259; 11, MRS5216.
d
Coumpound 5 is the dendrimer precursor of 8 and is similar to the dendrimer precursor of 6 and 7.
NA – not active in inhibition of radioligand binding (<10%) at 1 μM.
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Table 2
Maximal efficacy of (N)-methanocarba adenosine derivatives in a functional assay at the A3AR.















The efficacy at the human A3AR was determined by inhibition of forskolin-stimulated cyclic AMP production in AR-transfected CHO cells, as
described in the text. Percent inhibition is shown at the indicated concentration, in comparison to the maximal effect of a full agonist NECA at 1 μM.
Data are expressed as mean ± standard error (n = 3–5). ND, not determined.
b
Values from Tosh et al. (21).
c
EC50 values were determined with full curves for compounds 7 (0.12 ± 0.03 nM), 8 (1.36 nM), and 11 (2.93 ± 0.37 nM).
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